Janet Woodcock, FDA's Chief Medical Officer, on PAT, QbD and the Critical Path

 

In her plenary speech at IFPAC `07, FDA's Deputy Commissioner discussed the importance of PAT to the Agency's current objectives, not only Quality by Design, but the Critical Path.  She stressed the need for science-based approaches for both drug development and manufacuring, and outlined some of the challenges applying these concepts to the clinical area.  To download an audio tape of her speech, click here.  To read a full transcript, click here.

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments